Home About us Services Discovery Programs Technologies News&Events Careers
 
Discovery Services
Contact   Download   Privacy   Disclaimer   Site map
High-Throughput Screening
 
Assay Development
High-Throughput
Screening
Compound Collections for Customer Screening
Compound Profiling
Hits-to-Leads
 

Axxam’s labs are equipped with two state-of the-art screening stations designed for running 384 MTP format biochemical and cell based assays using luminescent or fluorescent based readouts.We offer the highest level of expertise and knowledge in configuration of the assay to make the most of every screening campaign.

We can conduct high-throughput screening by using either Axxam’s Compound Collections or any libraries that is provided to us. We have excellent storage facilities and practice the state of the art, handling and tracking standards with all our compound collections. Automation is used in any possible step of the process to decrease the change of undesired human errors.

  • Adaptation of the assay to the specific screening conditions
  • Pilot test performed on a sub-set of compounds to check the assay performance
  • Primary screening and hit identification
  • Hit-confirmation
  • Hit validation
  • Specificity testing
  • Comprehensive written report

At the end of the screening campaign, we will provide more than just a list of "hits" to our clients. Our emphasis is on high-quality data. That means attention to every detail during the complete project - careful choices of readout technologies, proper concentrations for reference ligands, effective counter-screens and more.

To receive more information on our screening services, contact us

Click on the link below to see more details on the process of High Throughput Screening at Axxam.

Learn more [...]

We can screen almost any target relevant to the pharmaceutical industry, including GPCRs, nuclear hormone receptors, ion channels, and enzymes. You benefit from the tight coupling between assay development and screening at Axxam. First, assays can move seamlessly from assay development into HTS with minimal delay if you also partner with Axxam for assay development. Second, optimal performance of the screening campaign is ensured with scientists from both groups committed to the success of the complete project.

The flexible screening facility we have created can adapt to the demands of multiple assay formats. Our main screening platform is built around a CyBio® screening system for 384-MTPs. For luminescent assays we employ either a CyBio® Lumax HTS - a highly-sensitive luminescent plate reader or the luminescence mode of the integrated FLIPRTETRA instrument from Molecular Devices. The latter instrument is also used for fluorescence mode assays, since it permits a wide range of excitation/emission options. We also utilize more specialized fluorescence-based plate readers for particular assays if advantageous. Even if you provide a fully-configured assay, our experienced assay development scientists can offer fine adjustments to increase the quality of screening campaign.

All screening data are automatically deposited into our custom relational database. Automated real-time data processing allows us to retest those plates that do not meet our strict quality-control parameters for Z', hit distribution and failed wells the same day. Sophisticated data processing methodologies monitor for systematic errors. All putative hits discovered in the initial screen are rapidly cherry-picked retested by multi-well hit confirmation experiments on our automated system to confirm and extend the initial finding. Finally the IC/EC50 values for the confirmed hits will be determined. Data reporting back to the client can be done chosing from a variety of options including simple text or Excel tables, database exports, and graphical views using Spotfire® or GeneData Screener® visualizations.